Skip to main content

Table 2 Summary of plasma pro-inflammatory cytokines levels at diagnosis in patients with NSCLC

From: Plasma RANTES, IL-10, and IL-8 levels in non–small-cell lung cancer patients treated with EGFR-TKIs

Case

Histrogical type

EGFR mutation status

Brinkman index

Treatment agent

Response

IL-8 (ng/mL)

IL-10 (ng/mL)

RANTES (pg/ml)

1

Ad

Ex21 L858R

900

gefitinib

PR

5.79

1.67

2

2

Ad

Ex21 L858R

0

erlotinib

PR

3.33

94.2

1.41

3

Ad

Ex19 del

0

erlotinib

PR

4.09

126

2.13

4

Ad

Ex21 L858R

0

gefitinib

PR

3.92

18.1

1.85

5

Ad

Ex21 L858R + Ex19 del

370

erlotinib

PR

21.9

1.23

2.11

6

Ad

Ex19 del

0

erlotinib

PR

7.05

1.37

2.56

7

Ad

Ex19 del

0

gefitinib

PR

4.82

1.59

2.02

8

Ad

Ex21 L858R

1640

gefitinib

PR

54.9

2.7

2.38

9

Ad

negative

400

erlotinib

SD

34.9

3.39

3.66

10

Ad

negative

0

erlotinib

SD

27.1

4.94

2.25

11

Ad

unknown

1800

erlotinib

SD

NE

NE

NE

12

Sq

Ex19 del

3840

gefitinib

SD

12.6

1.1

1.98

13

Ad

Ex19 del

30

erlotinib

SD

5.27

0.69

2.66

14

Ad

Ex19 del

0

erlotinib

SD

10.5

0.85

2.5

15

Ad

unknown

300

erlotinib

SD

7.69

2.61

1.7

16

La

negative

2080

erlotinib

SD

NE

NE

NE

17

Sq

Ex21 L858R

750

erlotinib

SD

11.6

56.3

3.06

18

Ad

unknown

600

erlotinib

SD

13.7

1.1

2.82

19

Ad

Ex21 L858R

0

erlotinib

SD

20.6

11.6

0.783

20

Ad

Ex19 del

0

erlotinib

SD

14.8

2.07

2.02

21

Ad

Ex21 L858R + Ex19 del

0

gefitinib

SD

3.04

1.3

1.76

22

Ad

Ex19 del

200

gefitinib

SD

10.9

1.59

1.91

23

Sq

unknown

1560

erlotinib

PD

NE

NE

NE

24

Ad

negative

1080

erlotinib

PD

25.2

8.15

1.57

25

Ad

unknown

0

erlotinib

PD

NE

NE

NE

26

Ad

Ex18 G719A

2000

erlotinib

PD

11.6

4.48

3.12

27

Ad

unknown

1410

erlotinib

PD

NE

NE

NE

28

Ad

Ex19 del

1000

gefitinib

PD

9.44

2.25

2.89

29

Ad

negative

1100

erlotinib

PD

56.3

5.63

2.16

30

Ad

negative

2000

erlotinib

PD

15.6

0.85

0.292

31

Ad

negative

825

erlotinib

PD

8.27

1.59

2.13

32

Ad

Ex21 L858R

0

erlotinib

PD

5.34

7.05

1.7

33

Ad

negative

1680

erlotinib

PD

57.7

1.63

2.06

  1. NSCLC, Non-small-cell lung cancer; Ad, Adenocarcinoma; Sq, Squamous cell carcinoma; La, Large-cell carcinoma; Ex, Exon; del, Deletion; PR, Partial response; SD, stable disease; PD, Progression disease; IL-8, Interleukin-8; IL-10, Interleukin-10; RANTES, Regulated upon activation normal T-cell expressed and secreted.